Amazon India has officially made its foray into the diagnostics space, launching a new at-home service called Amazon Diagnostics. Available in six cities—Bengaluru, Delhi, Gurgaon, Noida, Mumbai, and Hyderabad—the platform allows users to book lab tests, schedule appointments, and receive digital reports straight through the Amazon app.
In its first phase, the service spans more than 450 pin codes and gives access to over 800 diagnostic tests. Customers can get samples collected from their doorstep in as little as 60 minutes, with reports for routine tests delivered digitally in just six hours.
To pull this off, Amazon has tied up with Orange Health Labs, an accredited diagnostic provider that already claims to run “the world’s fastest reverse logistics system” for blood samples. Orange Health co-founder Dhruv Gupta said the company has built an on-demand collection system that can get to customers in as little as 30 minutes.
While several other players like Thyrocare, Healthians, and Metropolis are already jostling for space in this market, Amazon seems to be taking a different route—no flashy discounts or price wars. Instead, the idea is to provide reliable services through a trusted interface.
Amazon Diagnostics is the latest piece in the company's broader health-tech ambitions in India. Under the banner Amazon Medical, the platform already offers teleconsultations and medicine delivery. Diagnostics adds one more layer to this expanding health services ecosystem.
Jayaramakrishnan Balasubramanian, who leads the medical category at Amazon, said the diagnostics sector in India is both “underpenetrated and fragmented”—which makes it ripe for disruption. According to him, there’s plenty of room to grow, especially in routine and preventive testing, which currently make up a small portion of the overall market.
India's diagnostic industry is valued at about $12 billion as of financial year 2024, growing at a steady 8 % CAGR over the past five years. The organised segment, though still only 15 % of the total market, has outpaced overall growth with a 12 % CAGR.
However, most of this market—around 85 %—is still dominated by illness-related testing. That gives established players a solid edge, especially those with a strong network of labs and brand trust.
At the same time, industry insiders feel there’s plenty of opportunity, especially as lifestyle diseases like diabetes, kidney disorders and heart conditions require regular check-ups. The preventive diagnostics segment, though currently just 12 % of the market, is expected to gain traction in the coming years.
